We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.
- Authors
Caputo, Francesco; Santini, Chiara; Bardasi, Camilla; Cerma, Krisida; Casadei-Gardini, Andrea; Spallanzani, Andrea; Andrikou, Kalliopi; Cascinu, Stefano; Gelsomino, Fabio
- Abstract
Colorectal cancer (CRC) is one of the leading causes of mortality and morbidity in the world. It is a heterogeneous disease, which can be classified into different subtypes, characterized by specific molecular and morphological alterations. In this context, BRAF mutations are found in about 10% of CRC patients and define a particular subtype, characterized by a dismal prognosis, with a median survival of less than 12 months. Chemotherapy plus bevacizumab is the current standard therapy in first-line treatment of BRAF-mutated metastatic CRC (mCRC), with triplet (FOLFOXIRI) plus bevacizumab as a valid option in patients with a good performance status. BRAF inhibitors are not so effective as compared to melanoma, because of various resistance mechanisms. However, the recently published results of the BEACON trial will establish a new standard of care in this setting. This review provides insights into the molecular underpinnings underlying the resistance to standard treatment of BRAF-mutated CRCs, with a focus on their molecular heterogeneity and on the research perspectives both from a translational and a clinical point of view.
- Subjects
COLORECTAL cancer; BEVACIZUMAB; BRAF genes; P53 antioncogene; CANCER chemotherapy
- Publication
International Journal of Molecular Sciences, 2019, Vol 20, Issue 21, p5369
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms20215369